Oliyai Consulting Information

Oliyai Consulting Corporation (OCC) is a premier consulting firm serving the pharmaceutical and biotechnology industries, focused on Chemistry, Manufacturing, and Controls (CMC). We have partnered with 150+ clients, from large pharma to emerging startups and venture capital firms, helping accelerate drug development from lead optimization through commercialization. Our 170+ subject matter experts bring deep experience across drug development, manufacturing, and commercialization. With strategic relationships across the global CRO and CDMO network, we combine integrated strategic guidance and hands-on execution to address challenges across a wide range of therapeutic modalities, including: ▪Small molecules and peptides ▪Biologics ▪Antibody-drug conjugates (ADCs) ▪Oligonucleotides (siRNA, mRNA, and ASOs) ▪Cell therapies ▪Drug–device combination products OCC’s experience spans oral, injectable (IV, IM, SC, ICV, IVT, IT, and LAI), inhalation, nasal, ophthalmic, and pediatric formulations. We provide phase-appropriate regulatory, quality, and compliance support and are actively involved in numerous IND, IMPD, NDA, MAA, and BLA submissions. Beyond CMC, OCC’s capabilities extend to preclinical development, patent litigation support, and organizational development. We tailor our support to each client’s needs and internal capabilities, from targeted support and due diligence to augmenting internal teams and providing end-to-end CMC support. OCC was founded by Dr. Reza Oliyai, a pharmaceutical industry leader with 30+ years of experience in drug development, manufacturing, and commercialization. Leveraging his experience from Gilead and OCC, Dr. Oliyai has contributed to the development of 300+ drug candidates and global commercialization of 33 medicines. Our mission is to help companies navigate complexity, mitigate risk, accelerate development, and bring innovative medicines to patients. To learn more, please contact reza.o@oliyaiconsulting.com.